![](https://endpts.com/wp-content/uploads/2023/07/Christine-Ann-Miller-Melinta-feature.jpg)
Christine Anne Miller, Melinta Therapeutics CEO
Melinta secures $142M BARDA deal to target pediatric and 'biothreat' indications for antibiotics
Melinta Therapeutics secured a BARDA deal worth nearly $142 million to make two currently approved antibiotics available for children.
The deal comes roughly three years …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.